Appareil pulmonaire BP40657 A TWO-PART PHASE Ib/II STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS IN PATIENTS WITH STAGE IV;NONÀSMALL CELL LUNG CANCER Paris
Appareil pulmonaire ENTREE-LUNG (GSK 205801) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants Paris NICOLAS GIRARD
Appareil pulmonaire LUMINOSITY (M14-239) Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Appareil pulmonaire EDI-1001 Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Appareil pulmonaire MELROSE Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiological progression : the MELROSE trial Paris
Appareil pulmonaire MK7902-007 (LEAP-007) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007) Paris, Saint-Cloud
Appareil pulmonaire AMG20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C. Paris NICOLAS GIRARD
Appareil pulmonaire J10-MC-JZHB A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer Paris
Appareil pulmonaire MK7902-008 (LEAP-008) A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008) Paris CATHERINE DANIEL
Appareil pulmonaire AcceleRET (BLU-667-2303 ) AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC Paris NICOLAS GIRARD